Navigation Links
Study Shows Nonprescription LCD Topical Solution is More Effective than Prescription-Strength Calcipotriol Cream for Moderate Plaque Psoriasis
Date:3/10/2009

- Significant efficacy differences widen 6 weeks after treatment stops -

SAN FRANCISCO, March 10 /PRNewswire/ -- A nonprescription topical solution made with a new formulation of liquor carbonis distillate (LCD), known as PSORENT(R), is significantly more effective than prescription-strength calcipotriol cream in improving and controlling the symptoms of plaque psoriasis, according to research findings presented at the American Academy of Dermatology's 2009 Annual Meeting. Significant efficacy differences favoring LCD solution over a 12-week treatment phase were also pronounced after treatment stopped, during a 6-week regression phase that was the focus of the today's presentation. The research, a randomized, investigator-blind, active-controlled study of 60 adults with moderate plaque psoriasis, was conducted by a team of investigators at the Clinical Unit for Research Trials in Skin (CURTIS) at Massachusetts General Hospital in Boston, Massachusetts.

"We knew, based on the preliminary study results we presented at the summer AAD, that in the treatment phase of this study, twice-daily LCD outperformed calcipotriol cream for control of psoriasis symptoms," said Alexa Kimball, MD, MPH, a CURTIS researcher who was also a study investigator and author. "But we were encouraged by the fact that the improvements also persisted longer after patients stopped their twice-daily treatments for six weeks."

The team's conclusions are based on data from 55 patients who received treatment for up to 12 weeks and 43 patients who returned for re-assessment 6 weeks after treatment stopped. Its main findings include:

  • LCD therapy produced a significantly better reduction in psoriasis severity than calcipotriol therapy in 12 weeks based on PASI 50 (67% vs. 36%) and PASI 75 (37% vs. 0%) achievers and percent change in PASI (58% vs 37%) and PGA scores (P<0.05).
  • Significantly fewer LCD-treated patients than calcipotriol-treated patients regressed to initial disease severity within 6 weeks of stopping treatment (P</=0.005).
  • PASI scores and PGA scores worsened significantly after stopping calcipotriol therapy but not after stopping LCD therapy (P</=0.05).
  • Within 6 weeks of completing treatment, LCD-treated patients reported better control of a range of psoriasis symptoms -- including scaling/flaking, redness, skin texture, itch, overall appearance, and overall discomfort -- than calcipotriol-treated patients.
  • Patients' rated LCD solution and calcipotriol cream as comparable for convenience, irritation potential, and aesthetic attributes (e.g., staining, scent).

Dr. Kimball said their results should be important to a wide range of psoriasis patients because they indicate that this nonprescription therapy, "has a compelling efficacy and aesthetic profile." Psoriasis experts asked to comment on the study seem to agree on its significance.

"Because no single treatment is right for everyone, dermatologists are always looking for new ways to improve outcomes for their psoriasis patients," said Mark Lebwohl, MD, chairman of the Department of Dermatology at The Mount Sinai School of Medicine in New York. "The results of this trial suggest that LCD may be an appropriate treatment choice for psoriasis patients with mild or moderate disease."

Jerry Bagel, MD, Windsor Dermatology, said that "a new therapy that is easy for patients to use, cosmetically preferable, and that has greater proven efficacy than a prescription medication with the safety profile of an OTC, is certainly good news for psoriasis patients."

About PSORENT(R)

PSORENT(R) is a new leave-on topical solution that has the proven efficacy of a prescription medication but is available OTC. This aesthetically advanced, quick-drying, solution is highly effective, easy and pleasant to use, and may help increase patient satisfaction and compliance.

PSORENT(R) is supplied in 100 mL bottles fitted with a convenient "dab-on" applicator that allows patients to treat themselves without touching the medication or their plaques. PSORENT(R) is sold through physicians' offices and is available online at www.psorent.com.

About NeoStrata

PSORENT(R) is marketed by NeoStrata Company, Inc. Located in Princeton, NJ, NeoStrata develops and markets advanced therapeutic and cosmetic dermatological products through consumer outlets and physicians' offices in the United States and internationally through physicians' offices, pharmacies, and spas.

More information is available at www.neostrata.com and www.psorent.com.

    Media contact
    Barbara Green
    NeoStrata Company, Inc.
    609-986-2971
    bgreen@NeoStrata.com


'/>"/>
SOURCE NeoStrata Company, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. UM study reveals demographic trend of the Jewish population in Broward County
2. Shootings Linked to Alcohol-to-Go Outlets, Study Finds
3. Study shows that maintenance rituximab is useful for advanced indolent lymphoma
4. Study Links Blood Type and Pancreatic Cancer
5. New study identifies risk factors in severity of flat head syndrome in babies
6. New Study Shows That One-Third of Shelter Youth Have Been Institutionalized; Almost One-Half Suffered Violence in the Home
7. Beaumont Launches 1st U.S. Adult Human Stem Cell Study for Stress Urinary Incontinence
8. Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows
9. Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
10. Study Shows 80% of Adults with Peripheral Arterial Disease Go Undiagnosed
11. Study finds pay for performance stimulates changes in medical practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... Global ... diseases through research, education and awareness, today announced the appointment of Timothy J. ... microbiologist, Dr. Sellati has more than 20 years of research experience with Lyme ...
(Date:9/21/2017)... ... September 21, 2017 , ... SABRE is raising awareness about personal ... to the end of November. , The Chicago, Illinois, based self-defense brand has been ... them about the ease of taking their personal safety into their own hands. , ...
(Date:9/21/2017)... Virginia (PRWEB) , ... September 21, 2017 , ... ... health in their communities, nine governmental public health departments have been awarded five-year ... accreditation decisions mean that the benefits of being served by a PHAB-accredited ...
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center for Children® ... the election of Yie-Hsin Hung to the Board of Directors. , “The New ... Directors. Ms. Hung is an invaluable addition to our team,” said Vincent Strully, Jr., ...
(Date:9/21/2017)... ... ... FlipBelt, the fitness brand that specializes in problem solving fitness accessories, has ... the launch of their FlipBelt Crops. , The new fitness bottoms feature an integrated ... at the gym, on the trail, or on-the-go. , “We always thought the FlipBelt ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... Sept. 8, 2017 Dealmed Medical Supplies, ... of medical equipment, supplies, drugs, vaccines, and specialty medical ... into an agreement to acquire Vantage Medical Supplies, a ... Holtsville, New York . ... new and emerging medical practices, will operate under the ...
(Date:9/7/2017)... Sept. 7, 2017  Eli Lilly and Company ... to streamline operations to more efficiently focus resources ... cost structure. Global workforce reductions, including those from ... to impact approximately 3,500 positions. ... annualized savings of approximately $500 million that will ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris ... focused on fulfilling the promise of precision medicine, ... validate the benefits of its molecular profiling approach ... utilized comprehensive genomic profiling plus (CGP+) with Caris ... patient,s tumor on a molecular level, leading to ...
Breaking Medicine Technology: